Vigabatrin: Lessons Learned From the United States Experience

Update item information
Title Vigabatrin: Lessons Learned From the United States Experience
Creator Rod Foroozan, MD
Affiliation Baylor College of Medicine, Houston, Texas
Abstract Vigabatrin was introduced as an antiseizure medication in the United Kingdom in 1989 and was extensively used until 1997 when concerns arose regarding peripheral visual field loss. When the drug was approved in the United States in 2009, it carried a black box warning for the risk of permanent visual loss, and the pharmaceutical company was mandated to create a drug registry to assess for visual deficits. The vigabatrin drug registry has documented a relatively large percentage (37%) of preexisting, baseline visual deficits and a paucity (2%) of potential new visual findings. The vigabatrin vision study, a prospective, longitudinal, single-arm, open-label study, confirmed that adult patients with refractory complex partial seizures had a large number of visual deficits at baseline. An unexpected finding during the first year of therapy with vigabatrin was an increase in retinal thickness on optical coherence tomography. The experience from vigabatrin in the United States emphasizes the importance of baseline eye findings when considering the potential of drug toxicity involving the visual pathways.
OCR Text Show
Publisher Lippincott, Williams & Wilkins
Date 2018-12
Type Text
Source Journal of Neuro-Ophthalmology, December 2018, Volume 38, Issue 4
Language eng
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s6z65pz0
Setname ehsl_novel_jno
Date Created 2020-01-08
Date Modified 2020-03-23
ID 1500787
Reference URL
Back to Search Results